USPTO serial 79408189
ALAYA.BIO
Reviewed by CopyMark Law Group
Status 645Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- RUIZ SANTIAGO, REBECCA E
- Law office
- TMO LAW OFFICE 130
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with ALAYA.BIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Boris Umansky
Boris Umansky Ladas & Parry LLP224 S. Michigan Avenue, Ste. 1600Chicago, IL 60604United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biotechnology-derived products and preparations applied to the medical field, namely, in vivo cell and tissue reprograming pharmaceutical preparations for medical purposes for treating any conditions requiring cell and gene therapy; gene and cell therapy products and preparations, namely, cells targeting polymeric nanoparticle based on vector payloads for medical purposes; medical products, substances and preparations, namely, biotechnology-derived products and preparations being cell targeting pharmaceutical preparations comprising polymeric nanoparticles based on vector payloads and pharmaceutical products for immunotherapy and cancer treatment, autoimmune diseases, genetic diseases, diseases affecting the central nervous system; none of the aforementioned goods relating to or being in the nature of nutritional supplements | ACTIVE | — |
| 042 | Medical research; pharmacological research being pharmaceutical research services; research and development in the field of biotechnology; biotechnology advice, namely, consulting services in the field of biotechnology and the development of pharmaceuticals for cell and gene therapy; preparation of reports in the field of biotechnology for scientific research purposes; information about scientific research in the field of biochemistry and biotechnology; scientific research in the fields of cell therapy and gene therapy; scientific research in the fields of in-vivo gene therapy and cell therapy; medical and scientific research in the field of immunotherapy; medical and scientific research in the field of oncology; medical and scientific research in the field of autoimmune disease; medical and scientific research in the field of genetic disease; medical and scientific research in the field of diseases affecting the central nervous system | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 22, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 11, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 11, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 11, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Apr 16, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 30, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 29, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 11, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 11, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 11, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 30, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 30, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 30, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 19, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 31, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 31, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 26, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 25, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 3, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 1, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 1, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 31, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |